Butzkueven, H. Et Al. 2022. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study. 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , (Amsterdam, Netherlands), 384-386.

Butzkueven, H., Spelman, T., ÖZAKBAŞ, S., Laureys, G., Van Hijfte, L., Alroughani, R., ... Menoyo, J. L. S.(2022). Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study . 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (pp.384-386). Amsterdam, Netherlands

Butzkueven, H. Et Al. "Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study," 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 2022

Butzkueven, H. Et Al. "Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.384-386, 2022

Butzkueven, H. Et Al. (2022) . "Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.384-386.

@conferencepaper{conferencepaper, author={H. Butzkueven Et Al. }, title={Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study}, congress name={38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={384-386} }